Danaher Corporation (DHR)vsMedpace Holdings Inc (MEDP)
DHR
Danaher Corporation
$187.15
-1.55%
HEALTHCARE · Cap: $134.43B
MEDP
Medpace Holdings Inc
$466.80
+1.32%
HEALTHCARE · Cap: $13.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 871% more annual revenue ($24.57B vs $2.53B). MEDP leads profitability with a 17.8% profit margin vs 14.7%. DHR appears more attractively valued with a PEG of 1.23. MEDP earns a higher WallStSmart Score of 70/100 (B-).
DHR
Buy60
out of 100
Grade: C
MEDP
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.6%
Fair Value
$135.07
Current Price
$187.15
$52.08 premium
Margin of Safety
+40.8%
Fair Value
$716.04
Current Price
$466.80
$249.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.2%
Generating 1.7B in free cash flow
Every $100 of equity generates 70 in profit
Revenue surging 32.0% year-over-year
Strong operational efficiency at 21.6%
Earnings expanding 26.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
4.6% revenue growth
ROE of 7.0% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Revenue Growth, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 21.6%. Revenue growth of 32.0% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : MEDP
The primary concerns for MEDP are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
DHR profiles as a value stock while MEDP is a growth play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.46 — expect wider price swings.
MEDP is growing revenue faster at 32.0% — sustainability is the question.
DHR generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (70/100 vs 60/100), backed by strong 17.8% margins and 32.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?